WFH Guidelines for the Management of Hemophilia, 3rd edition
2020 · Haemophilia · 1,811 citations
https://doi.org/10.1111/hae.14046
S
Steven W. Pipe
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
318
Papers
10.3K
Citations
49
h-index
151
i10-index
Steven W. Pipe is an academic researcher from University of Michigan–Ann Arbor. The author has contributed to research in topics: Hemophilia Treatment and Research & Blood Coagulation and Thrombosis Mechanisms & Platelet Disorders and Treatments. The author has an h-index of 49, co-authored 271 publications.
ORCID: 0000-0003-2558-2089Papers by this author
worksGene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023 · New England Journal of Medicine · 314 citations
https://doi.org/10.1056/nejmoa2211644
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
2019 · Blood Advances · 128 citations
https://doi.org/10.1182/bloodadvances.2019000811
Mortality in congenital hemophilia A – a systematic literature review
2020 · Journal of Thrombosis and Haemostasis · 61 citations
https://doi.org/10.1111/jth.15189
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
2022 · Blood Advances · 56 citations
https://doi.org/10.1182/bloodadvances.2022008886
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
2024 · Journal of Thrombosis and Haemostasis · 44 citations
https://doi.org/10.1016/j.jtha.2024.04.001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat